Lipid Nanoparticles Improve the Uptake of α-Asarone Into the Brain Parenchyma : Formulation, Characterization, In Vivo Pharmacokinetics, and Brain Delivery
Treatment of brain-related diseases is one of the most strenuous challenges in drug delivery research due to numerous hurdles, including poor blood-brain barrier penetration, lack of specificity, and severe systemic toxicities. Our research primarily focuses on the delivery of natural therapeutic compound, α-asarone, for the treatment of brain-related diseases. However, α-asarone has poor aqueous solubility, bioavailability, and stability, all of which are critical issues that need to be addressed. This study aims at formulating a lipid nanoparticulate system of α-asarone (A-LNPs) that could be used as a brain drug delivery system. The physicochemical, solid-state properties, stability, and in vitro and in vivo studies of the A-LNPs were characterized. The release of α-asarone from the A-LNPs was prolonged and sustained. After intravenous administration of A-LNPs or free α-asarone, significantly higher levels of α-asarone from the A-LNPs were detected in murine plasma and brain parenchyma fractions, confirming the ability of A-LNPs to not only maintain a therapeutic concentration of α-asarone in the plasma, but also transport α-asarone across the blood-brain barrier. These findings confirm that lipid nanoparticulate systems enable penetration of natural therapeutic compound α-asarone through the blood-brain barrier and may be a candidate for the treatment of brain-related diseases.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
---|---|
Enthalten in: |
AAPS PharmSciTech - 21(2020), 8 vom: 02. Nov., Seite 299 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Ramalingam, Prakash [VerfasserIn] |
---|
Links: |
---|
Themen: |
α-asarone |
---|
Anmerkungen: |
Date Completed 11.01.2021 Date Revised 04.12.2021 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.1208/s12249-020-01832-8 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM317085336 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM317085336 | ||
003 | DE-627 | ||
005 | 20231225162505.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1208/s12249-020-01832-8 |2 doi | |
028 | 5 | 2 | |a pubmed24n1056.xml |
035 | |a (DE-627)NLM317085336 | ||
035 | |a (NLM)33140227 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Ramalingam, Prakash |e verfasserin |4 aut | |
245 | 1 | 0 | |a Lipid Nanoparticles Improve the Uptake of α-Asarone Into the Brain Parenchyma |b Formulation, Characterization, In Vivo Pharmacokinetics, and Brain Delivery |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 11.01.2021 | ||
500 | |a Date Revised 04.12.2021 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Treatment of brain-related diseases is one of the most strenuous challenges in drug delivery research due to numerous hurdles, including poor blood-brain barrier penetration, lack of specificity, and severe systemic toxicities. Our research primarily focuses on the delivery of natural therapeutic compound, α-asarone, for the treatment of brain-related diseases. However, α-asarone has poor aqueous solubility, bioavailability, and stability, all of which are critical issues that need to be addressed. This study aims at formulating a lipid nanoparticulate system of α-asarone (A-LNPs) that could be used as a brain drug delivery system. The physicochemical, solid-state properties, stability, and in vitro and in vivo studies of the A-LNPs were characterized. The release of α-asarone from the A-LNPs was prolonged and sustained. After intravenous administration of A-LNPs or free α-asarone, significantly higher levels of α-asarone from the A-LNPs were detected in murine plasma and brain parenchyma fractions, confirming the ability of A-LNPs to not only maintain a therapeutic concentration of α-asarone in the plasma, but also transport α-asarone across the blood-brain barrier. These findings confirm that lipid nanoparticulate systems enable penetration of natural therapeutic compound α-asarone through the blood-brain barrier and may be a candidate for the treatment of brain-related diseases | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a brain distribution | |
650 | 4 | |a lipid nanoparticles | |
650 | 4 | |a pharmacokinetics | |
650 | 4 | |a stability | |
650 | 4 | |a α-asarone | |
650 | 7 | |a Allylbenzene Derivatives |2 NLM | |
650 | 7 | |a Anisoles |2 NLM | |
650 | 7 | |a Lipids |2 NLM | |
650 | 7 | |a asarone |2 NLM | |
700 | 1 | |a Ganesan, Palanivel |e verfasserin |4 aut | |
700 | 1 | |a Prabakaran, D S |e verfasserin |4 aut | |
700 | 1 | |a Gupta, Pardeep K |e verfasserin |4 aut | |
700 | 1 | |a Jonnalagadda, Sriramakamal |e verfasserin |4 aut | |
700 | 1 | |a Govindarajan, Karthivashan |e verfasserin |4 aut | |
700 | 1 | |a Vishnu, Revuri |e verfasserin |4 aut | |
700 | 1 | |a Sivalingam, Kalaiselvi |e verfasserin |4 aut | |
700 | 1 | |a Sodha, Srushti |e verfasserin |4 aut | |
700 | 1 | |a Choi, Dong-Kug |e verfasserin |4 aut | |
700 | 1 | |a Ko, Young Tag |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t AAPS PharmSciTech |d 2000 |g 21(2020), 8 vom: 02. Nov., Seite 299 |w (DE-627)NLM126699429 |x 1530-9932 |7 nnns |
773 | 1 | 8 | |g volume:21 |g year:2020 |g number:8 |g day:02 |g month:11 |g pages:299 |
856 | 4 | 0 | |u http://dx.doi.org/10.1208/s12249-020-01832-8 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 21 |j 2020 |e 8 |b 02 |c 11 |h 299 |